Proposed age-adjusted eGFR thresholds for CKD 👇
#Nephpearls #NephSky

eGFR 75 for ages <40 years
eGFR 60 for 40-65 years
eGFR 45 for >65 years

👉 link.springer.com/book/10.1007...
👉 pubmed.ncbi.nlm.nih.gov/31506289/

I really enjoyed this lecture and I consider it a must watch to understand how dialysis facilities work.

I am finding it very hard to connect with people here on BlueSky.

Phosphorus-independent role of FGF23 in erythropoiesis and iron homeostasis
#nephsky
journals.plos.org/plosone/arti...

The @freelyfiltered.bsky.social discusses the fine art required in prescribing an MRA in heart failure

www.nephjc.com/freelyfilter...
feat @captainchloride.bsky.social @kidneyboy.bsky.social @jordybc.bsky.social @medpeedskidneys.bsky.social and special guest @brendonneuen.bsky.social

Extended-release Nifedipine is a medication that I see very commonly misused. I see doses as high as 90 mg once a day. Please, at least divide the dosing twice a day, the plasma half-life of about 4 to 7 hours.

www.ncbi.nlm.nih.gov/books/NBK537...

In patients whose immunosuppression regimen was changed from a CNI-based regimen to Belatacept:
- 5% incidence of TCMR and 1% AMR.
- Most TCMR was early after conversion <6 months.
- Seems less frequent than with DeNovo use.

t.co/vK3tgzk9xR

Do you believe in AKI due to IV contrast exposure?

pubmed.ncbi.nlm.nih.gov/39186608/

Urine complement-related proteins are a promising biomarker in IgA nephropathy.

Urine eosinophils are useless in diagnosing interstitial nephritis. Stop ordering them.

pmc.ncbi.nlm.nih.gov/articles/PMC...

In patients with T2DM and CKD, the dual GLP1 and glucagon receptor agonist Cotadutide significantly reduced UACR, suggesting a protective effect.

Improvement in progression of CKD demonstrated by the FLOW trial in which patients with CKD received semaglutide vs standard of care, might be confounded by concomitant weight loss.

pubmed.ncbi.nlm.nih.gov/39566843/

Klotho in its soluble form protects against uremic cardiomyopathy-induced cardiac dysfunction by regulating intracellular Ca2+, acting directly and independently from the kidney on cardiac tissue, protecting the kidney-heart axis through its anti-inflammatory action.

t.co/TAh2WgWUiM

In this secondary analysis of the STARRT-AKI, surviving patients after a severe AKI were evaluated to determine if RRT initiation strategy had an effect on CKD progression. Patients with severe AKI had a high chance of progression to CKD regardless of the RRT strategy that was used.

In patients with high ileostomy output after IBD the risk of kidney disease increased, with HR of 2.5 for AKI and 1.5 for CKD.

cghjournal.org/article/S154...

PPIs, such as pantoprazole, are potent inhibitors of OCT2. This raises the possibility that the decline in eGFR associated with PPI usage may result from impaired tubular secretion rather than a true decrease in GFR or impaired renal function.

"Despite recent trials suggesting no benefit of alkali therapy in preserving kidney function, the inconsistent clinically meaningful group differences and sufficient power make us believe that effects on CKD progression remain inconclusive."

GLP1RA and SGLT2i remain underutilized, especially in high-risk populations. Of 280,024 patients with T2DM and different degrees of CV disease, only 18% were prescribed a GLP1RA, 10% were an SGLT2i, and 8% were prescribed both during the study period.